Three cases of feline hypereosinophilic syndrome treated with imatinib mesylate (2023)

section cutouts

autumn 1

A 6-year-old neutered male domestic shorthair cat was referred for severe pruritic eosinophilic dermatitis of more than 5 years' duration and associated with 2-month steroid treatment, worsening skin and oral lesions, ptyalism, and eating behavior pain, weight loss and lethargy. The initial lesions were a linear granuloma located on the lower limbs and an eosinophilic plaque located on the inner thigh. A limited antigenic diet study (DR21 Royal Canin), Flea Control


In humans, hypereosinophilic syndrome (HES) is defined as a heterogeneous group of rare diseases characterized by the presence of marked eosinophilia in peripheral blood (greater than 1.5 × 109/L), the absence of a secondary cause for eosinophilia, and evidence of organ damage associated with eosinophils [5], [6].

Recent techniques have allowed the characterization of human HES subtypes through their precise immunological and genetic abnormalities. The two best described subtypes are lymphocytic.


The surprising improvement with imatinib mesylate in these patients, and its excellent tolerability after five years of empirical treatment in one of them, suggests that this drug is useful in the management of feline hypereosinophilic syndrome and can significantly improve its prognosis in patients who have been treated so far. exceptional could be condemned.

Finally, other tyrosines are due to their availability as a canine drug, their apparent lack of toxicity in cats, as well as their more appropriate spectrum of activity.

disclosure of interest

The authors declare that they have no conflict of interest related to this article.

Featured Articles (6)

  • Investigation article

    A frameshift mutation of exon 53 in CUBN abolishes cubam function and causes Imerslund-Gräsbeck syndrome in dogs

    (Video) HES - Hypereosinophilic Syndrome Webinar, Part 1 (APFED)

    Cobalamin malabsorption, accompanied by selective proteinuria, is an autosomal recessive disease known as Imerslund-Gräsbeck syndrome in humans and is already found in dogs due to amniosis.AMN) mutations. The resulting B vitamin12Deficiency causes dyshematopoiesis, lethargy, growth retardation, and life-threatening metabolic disorders in adolescence. We studied 3 border collie relatives with cobalamin malabsorption and mapped the disease site in affected dogs to a 2.9 Mb region of homozygosity on canine chromosome 2. The region includedCUBNO, the locus encoding cubilin, a peripheral membrane protein that together with AMN forms the functional intrinsic factor cobalamin receptor expressed in the ileum and a multiligand receptor in the renal proximal tubules. Cobalamin malabsorption and proteinuria with CUBN ligands were demonstrated by radiolabeled cobalamin uptake and SDS-PAGE studies, respectively.CUBNOIn both the ileum and kidney of affected dogs, mRNA and protein expression were reduced by about 10-fold and about 20-fold, respectively. DNA sequencing revealed a single base deletion in exon 53, which predicted a translation frameshift and early stop codon, likely triggering nonsense-mediated mRNA decay. The mutant allele segregated with the disease in the border collie family. Border collie disease indicates that aCUBNOMutations that are C-terminal away from the cobalamin-intrinsic factor binding site can abolish receptor expression and cause Imerslund-Gräsbeck syndrome.

  • Investigation article

    Validation of a Clinically Applicable Flow Cytometry Assay for Immunoglobulin-Associated Platelet Detection in Dogs

    Veterinary Immunology and Immunopathology, Band 202, 2018, S. 109-114

    Thrombocytopenia is frequently encountered in veterinary practice when evaluating canine patients. It can occur in infectious, neoplastic, inflammatory, toxic, and immune-mediated conditions. Therefore, elucidating the underlying cause of thrombocytopenia can be challenging for veterinarians. In addition, determining whether an immune process might contribute to a patient's thrombocytopenia is important to refine the differences and improve understanding of a particular disease process. A possible test candidate for the development of a clinically applicable assay in dogs is flow cytometry. Therefore, the purpose of this study was to develop a clinically applicable direct and indirect flow cytometry assay for the detection of canine immunoglobulin-associated platelets. Direct and indirect flow cytometry was performed on nine healthy beagle dogs and twelve of the client's thrombocytopenic dogs at four time points: fresh, and after 24, 48, and 72 hours of storage at 4°C. In healthy dogs, there was no significant difference between fresh and 24- and 48-hour samples, but there was a significant difference between fresh and 72-hour samples. There were no significant differences between fresh and 24, 48, or 72 hour samples in dogs with thrombocytopenia. A cut-off value of ≤10% antibody binding was defined to distinguish negative and positive scores and was determined by serial direct flow assessments in a healthy dog. Based on this cut-off score, healthy and thrombocytopenic dogs were evenly classified at each time point. The mean intra-assay coefficient of variation for thrombocytopenic dogs was 4.32%. The indirect flow cytometry methods evaluated here did not provide reliable or repeatable results in healthy or thrombocytopenic dogs. Direct flow cytometry represents a potentially clinically useful test for the detection of immunoglobulin-associated platelets in dogs that can be processed and interpreted in a realistic time frame, allowing testing in larger numbers of patients. Based on the results of this study using our protocols, indirect flow cytometry in dogs was not clinically applicable.

    (Video) Hypereosinophilic Syndromes, Then and Now: Perspective Piece
  • Investigation article

    Evaluation of acute kidney injury in dogs with complicated or uncomplicated Babesia rossi infection

    Ticks and Tick-borne Diseases, Volume 11, Issue 3, 2020, Article 101406

    Dogs with babesiosis can have a number of complications, including acute kidney injury (AKI). The aim of this study was to characterize AKI in dogs with babesiosis caused byBabesia-Rotat presentation and after treatment. Thirty-five client-owned dogs withB. RottöneIn this prospective observational study, infected dogs and 10 control dogs were included. Blood and urine were collected.nena-dogs infected at presentation (T0, n=35), canal 24h (T24 hours, n=11) and after 1 month (T1 metro, n=9). The following biomarkers of urinary kidney injury were evaluated: urinary protein/creatinine ratio (UPC), biomarkers of urinary glomerular injury (immunoglobulin G (uIgG) and C-reactive protein (uCRP)), and biomarkers of urinary tubular injury (retinol-binding protein). . (uRBP) and neutrophil gelatinase-associated lipocalin (uNGAL)). Serum functional renal biomarkers were creatinine (sCr) and symmetric dimethylarginine (sSDMA). Postmortem kidney biopsies were analyzed by light and transmission electron microscopy.

    and t0, all biomarkers of kidney damage were significantly higher innena-infected dogs compared with healthy controls (P<0.001), whereas functional renal biomarkers were not significantly different (P>0.05). at t24 hours, all biomarkers of tubular urinary tract injury and UPC decreased significantly (P<0.01), whereas biomarkers of glomerular injury did not (P=0.084). at t1 metro, all biomarkers of urinary kidney injury were decreased to levels that were not significantly different from healthy controls (P > 0.5). No significant changes in renal functional biomarkers were observed after treatment (P>0.05). Dogs with complicated babesiosis had significantly higher biomarkers of glomerular injury, UPC, and sSDMA compared with uncomplicated cases (P<0.05), while all biomarkers of tubular injury and sCr were not significantly different (P>0 ,1).

    (Video) Evaluation of Hypereosinophilia (Sheikh)

    Dogs with babesiosis caused byB. RottöneDemonstrated transient renal injury recognized by all biomarkers of renal injury but not recognized by functional biomarkers. All infected dogs, regardless of disease severity, experienced comparable kidney damage based on tubular biomarker levels, whereas functional loss was seen more frequently in dogs with complicated babesiosis based on sSDMA results.

  • Investigation article

    Comparison of the pharmacodynamics of insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats

    Domestic Animal Endocrinology, Band 75, 2021, Artikel 106595

    Insulin glargine (IGla) is a synthetic analogue of recombinant human insulin that is commonly used in humans as a 24-hour basal insulin. The 300 U/mL (U300) formulation of IGla is associated with a longer duration of action and less intraday variability, making it a superior basal insulin compared to the 100 U/mL (U100) formulation. We hypothesize that IGlaU300 has a flatter time-effect profile and longer duration of action in healthy cats compared to IGlaU100. Seven healthy, neutered, specifically bred male cats were studied in a randomized crossover design. The pharmacodynamics of IGlaU100 and IGlaU300 (0.8 U/kg, subcutaneous) was determined by the isoglycemic clamp method. The response time profile of IGlaU300 was flatter compared to IGlaU100, as indicated by the lower peaks (5.6 ± 1.1 mg/kg/min and 8.3 ± 1.9 mg/kg/min, respectively;PAG= 0.04) with no difference in total metabolic effect (ME;PAG= 0.7) or duration of action (16.8 ± 4.7 h vs. 13.4 ± 2.6 h;PAG= 0.2). The highest proportion of ME at 12 to 24 hours post-injection (35 ± 23% vs. 7 ± 8%;PAG= 0.048) and less intraday variability of GIR% (7.8 ± 3.7% vs. 17.4 ± 8.2%;PAG= 0.03) supports a flatter time history profile of IglaU300. There were no differences in the beginning and end of the effect. In summary, although both formulations have a similar duration of action, well below 24 hours, the ME of IGlaU300 is more evenly distributed over a 24-hour period in healthy cats, making it a better candidate for those that are injected once a day. in diabetics.

  • Investigation article

    X-Linked Hypohidrotic Ectodermal Dysplasia: General Characteristics and Dental Abnormalities in Affected Dogs Compared with Human Dental Abnormalities

    Topics in Companion Animal Medicine, Band 35, 2019, S. 11-17

    (Video) Imatinib as a Paradigm of Targeted Cancer Therapies

    X-linked hypohidrotic ectodermal dysplasia (XLHED) is a genetic disorder characterized by abnormalities in ectodermal derivatives such as sweat glands, hair, and teeth. In animals, most cases have been reported in dogs, which present with characteristic congenital alopecia and develop abnormalities in the shape and number of teeth. Although the clinical phenotype of affected individuals is typical, this disease is almost unknown in veterinary clinical practice. In order to make it known, in this summary we have compiled the most important clinical and genetic aspects of XLHED, with special attention to dental anomalies.

  • Investigation article

    Fenofibrate Treatment for Severe Hypertriglyceridaemia in Dogs

    Domestic Animal Endocrinology, Band 74, 2021, Artikel 106578

    Lipid disorders are relatively common in dogs. Hyperlipidemia can be primary or secondary to other diseases. In humans, fenofibrate is used to control hypertriglyceridemia. There are no studies evaluating fenofibrate in hypertriglyceridaemia in dogs. The objective of the study was to evaluate the safety and efficacy of fenofibrate in the control of severe hypertriglyceridaemia in dogs. A total of 124 dogs (n=124) with severe hypertriglyceridaemia (>300 mg/dL, 3.39 mmol/L) were randomized to the fenofibrate group (n=64) and the diet group (n=60). Dogs in the fenofibrate group were treated with fenofibrate (10 mg/kg) once daily. Dogs in the diet group were treated with a low-fat (10%) diet. Serum concentrations of triglycerides (TG), total cholesterol (TC), liver enzymes, and creatine kinase were evaluated before and after 1 month of medical or dietary treatment. Triglyceride concentrations were reduced with fenofibrate (PAG< 0.001), and 85.93% of the dogs normalized their scores. Triglyceride concentrations also decreased with a low-fat diet (PAG< 0.001), but only 26.6% of the dogs normalized their values. Triglyceride concentrations were reduced with fenofibrate (PAG< 0.01) and with a low-fat diet (PAG<0.01). Of the cases with hypercholesterolemia, 53.7% and 50% of the dogs normalized their TC concentrations with fenofibrate and food, respectively. No significant side effects were observed (3% had diarrhoea). Fenofibrate was safe and effective in reducing and normalizing TG levels in dogs with severe hypertriglyceridemia, regardless of the cause of the hyperlipidemia. The low-fat diet effectively reduced, but did not normalize, TG concentrations. Fenofibrate and a low-fat diet were effective in reducing TC levels. This is the first study to examine fibrates in dogs with severe hypertriglyceridaemia and to compare the results with a low-fat diet.

    (Video) Current HES Treatment Options and Side Effects


1. IES Abstract Webinar - 6 October 2021
(International Eosinophil Society)
2. Patient Perspectives on Current Therapies for Hypereosinophilic Syndromes
3. Breakthrough in Cancer Treatments | Dr. Brian Druker | Talks at Google
(Talks at Google)
4. 12/13/16 Eosinophilic Syndromes
(UW AI Teaching Series)
5. Brian Druker (OHSU) Part 3: Extending the Imatinib Paradigm
6. Updates in Systemic Mastocytosis: Emerging Therapies for Advanced Disease Subtypes
(HMP Education)


Top Articles
Latest Posts
Article information

Author: Duane Harber

Last Updated: 06/08/2023

Views: 6530

Rating: 4 / 5 (51 voted)

Reviews: 82% of readers found this page helpful

Author information

Name: Duane Harber

Birthday: 1999-10-17

Address: Apt. 404 9899 Magnolia Roads, Port Royceville, ID 78186

Phone: +186911129794335

Job: Human Hospitality Planner

Hobby: Listening to music, Orienteering, Knapping, Dance, Mountain biking, Fishing, Pottery

Introduction: My name is Duane Harber, I am a modern, clever, handsome, fair, agreeable, inexpensive, beautiful person who loves writing and wants to share my knowledge and understanding with you.